ArticleStatistics in biopharmaceutical research2014
Bridging Solutions in Dose Finding Problems.
Article in Statistics in biopharmaceutical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Phase I design for partially ordered groups with late-onset toxicity.Clinical trials (London, England) · 2026Article
- Phase I/II Design for Selecting Subgroup-Specific Optimal Biological Doses for Prespecified Subgroups.Statistics in medicine · 2024Article
- Dose-finding based on feasibility and late-onset toxicity in adoptive cell therapy trials.Journal of biopharmaceutical statistics · 2024Article
- Concurrent dose-finding of a novel cancer drug with and without a second agent.Journal of clinical and translational science · 2023Article
- Bayesian Design for Identifying Cohort-Specific Optimal Dose Combinations Based on Multiple Endpoints: Application to a Phase I Trial in Non-Small Cell Lung Cancer.International journal of environmental research and public health · 2021Article
- Bridging across patient subgroups in phase I oncology trials that incorporate animal data.Statistical methods in medical research · 2021Article
- Estimating Similarity of Dose-Response Relationships in Phase I Clinical Trials-Case Study in Bridging Data Package.International journal of environmental research and public health · 2021Article
- An adaptive power prior for sequential clinical trials - Application to bridging studies.Statistical methods in medical research · 2020Article
- Consequences of Performing Parallel Dose Finding Trials in Heterogeneous Groups of Patients.JNCI cancer spectrum · 2019Article
- Shift models for dose-finding in partially ordered groups.Clinical trials (London, England) · 2019Article
- The Impact of Early-Phase Trial Design in the Drug Development Process.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Dose-escalation strategies which use subgroup information.Pharmaceutical statistics · 2018Article
- Isotonic designs for phase I trials in partially ordered groups.Clinical trials (London, England) · 2017Article
- A design for phase I trials in completely or partially ordered groups.Statistics in medicine · 2017Article
- Designs for phase I trials in ordered groups.Statistics in medicine · 2017Article
- Performance of toxicity probability interval based designs in contrast to the continual reassessment method.Statistics in medicine · 2017Article
- Identifying a maximum tolerated contour in two-dimensional dose finding.Statistics in medicine · 2017Article
- Innovations for phase I dose-finding designs in pediatric oncology clinical trials.Contemporary clinical trials · 2016Review
- Clinical trials: Early phase clinical trials-are dose expansion cohorts needed?Nature reviews. Clinical oncology · 2015Article
- A model-assisted design for partially or completely ordered groups.Pharmaceutical statisticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The idea of bridging in dose-finding studies is closely linked to the problem of group heterogeneity. There are some distinctive features in the case of bridging which need to be considered if efficient estimation of the maximum tolerated dose (MTD) is to be accomplished. The case of two distinct populations is considered. In the bridging setting we usually have in mind two studies, corresponding to the two populations. In some cases, the first of these studies may have been completed while the second has yet to be initiated. In other cases, the studies take place simultaneously and information can then be shared among the two groups. The methodological problem is how to make most use of the information gained in the first study to help improve efficiency in the second. We describe the models that we can use for the purpose of bridging and study situations in which their use leads to overall improvements in performance as well as cases where there is no gain when compared to carrying out parallel studies. Simulations and an example in pediatric oncology help to provide further insight.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.